Repositioning
Clinical Stage Drugs
For Rare and Common Diseases
with Unmet Need
Acctena's strategy is to bring selected drugs directly into phase 2 studies for new clinical use and expanded intellectual property
By evaluating study data and mechanism of action, experienced drug developers can identify diseases where these “abandoned” drugs can become beneficial medicines .
Our Platforms
Acctena is Built on
Two Platforms with Near Term PoC
Nuclear receptor agonist platform
Acctena’s drug has been in ~1000 patients in initially in other disorders by leading pharma company. Its safety and mode of action is well known.
READ MORE
Immuno-oncology platform
An engineered, tumor-targeted cytokine that has passed Phase 1b as a monotherapy by a leading biotech company, PoC planned in combination with checkpoint inhibitors in 1 year.
READ MORE
MESSAGE FROM OUR BOARD
"Acctena offers reduced risk for investors due to its diversified development portfolio consisting of drugs that have already been studied in man.
Kjell Stenberg
ACCTENA CEO & FOUNDER
Revive your clinical drug
Unlock the full potential of your abandonned clinical drug.
Apply for a chance to become part of Acctena's program.